Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APR-246 induces early cell death by ferroptosis in acute myeloid leukemia

7 Jan 2021

Abstract excerpt

APR-246 is a promising new therapeutic agent that targets p53 mutated proteins in myelodysplastic syndromes and in acute myeloid leukemia (AML). APR-246 reactivates the transcriptional activity of p53 mutants by facilitating their binding to DNA target sites. Recent studies in solid cancers have found that APR-246 can also induce p53-independent cell death. In this study, we demonstrate that AML cell death...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Epigenetics and DNA Methylation
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33406814
DOI: 10.3324/haematol.2020.259531

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APR-246 induces early cell death by ferroptosis in acute myeloid leukemiaPMID 33406814Read ↗

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.Semantic proximity Read ↗

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.Semantic proximity Read ↗

Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosisSemantic proximity Read ↗

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cellsSemantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.Semantic proximity Read ↗

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer TherapySemantic proximity Read ↗

Effect of Ferroptosis Inducers and Inhibitors on Cell Proliferation in Acute LeukemiaSemantic proximity Read ↗

COVID-19 concerns aggregate around plateletsSemantic proximity Read ↗

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.Semantic proximity Read ↗

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.